CLDI

0.47755.45%
DZ

Dmitriy Zamarin

Member of Scientific Advisory Board

Dr. Dmitriy Zamarin, M. D., Ph. D. has been a Member of Clinical Advisory Board at OverT Bio, Inc. since March 2026. Dr. Zamarin serves as Member of Medical Advisory Board at Calidi Biotherapeutics, Inc. Dr. Zamarin serves as a Member of Advisory Board at OmniCyte, LLC. Dr. Zamarin serves as Member of Scientific Advisory Board at Circio Holding ASA since October 2020. Dr. Zamarin serves as Member of Scientific Advisory Board at Memgen, Inc. He serves as the Member of Clinical Advisory Board at ImmunOs Therapeutics AG. Dr. Zamarin is the Medical Oncologist, Gynecologic Medical Oncology and Immunotherapeutics for Memorial Sloan Kettering Cancer Center. Previously he held positions as Research Fellow and Hematology/Oncology Fellow for Memorial Sloan Kettering Cancer Center. Zamarin is a medical oncologist specializing in the care of women with gynecologic cancers, including cervical, ovarian and endometrial cancers. Dr. Zamarin serves as a Member of Scientific Advisory Board at Memgen, LLC., since 2021. Dr. Zamarin has been Scientific Advisor at Tessa Therapeutics Pte Ltd. Dr. Zamarin is a medical oncologist at Memorial Sloan Kettering Cancer Center and specializes in the care of women with gynecologic cancers, including cervical, ovarian and endometrial cancers. Dr. Zamarin is a medical oncologist at Memorial Sloan Kettering Cancer Center and specializes in the care of women with gynecologic cancers, including cervical, ovarian and endometrial cancers. Dr. Zamarin is Member of Clinical Advisory Board at KaliVir Immunotherapeutics, Inc since December 2022. Dr. Zamarin is currently a Principal investigator and a translational Chair on multiple institutional and national clinical trials exploring novel immunotherapy combinations in gynecologic cancers and other solid tumors. Dr. Zamarin clinical and laboratory research is focused on the development of new ways to use the immune system to treat cancer. He is particularly interested in genetically engineered oncolytic viruses, an emerging class of immune therapeutic drugs that have shown significant clinical promise in the recent years. By manipulating the oncolytic viruses and the immune system, Dr. Zamarin is exploring different ways to enhance the immune recognition of tumors and to develop novel treatment strategies that would be applicable to different cancer types. Dr. Zamarin has received various awards for his work, including the 2014 Bladder Cancer Awareness Network Young Investigator Award, 2013 Conquer Cancer Foundation ASCO Young Investigator Award, the Damon Runyon Foundation Fellowship Award as well as the Ovarian Cancer Research Fund Liz Tilberis Early Career Award in 2017. Dr. Zamarin received his M. D. and Ph. D. from Mount Sinai School of Medicine, New York.

公司职务